Endocyte Inc (ECYT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Endocyte Inc (ECYT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH137442D
  • |
  • Pages: 41
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Endocyte Inc (Endocyte) is a biopharmaceutical company which develops targeted therapies for the treatment of cancer and inflammatory diseases. The company's pipeline products include EC1456, EC2629 used to treat solid tumors; EC1169, EC0652 targets prostate cancer; Vintafolide (EC145) for cancer; EC2319 used to treat inflammatory�diseases; EC0371 for the treatment of polycystic�kidney�disease. Endocyte's proprietary small molecule drug conjugate (SMDC) technology is used to create novel SMDCs and companion imaging agents for personalized targeted therapies. The company is developing therapeutic immunotherapy�approach�that�involves�the re-targeting�of�potent�immune�cells,�called�chimeric antigen receptor T-cell (CAR T-cell) to�fight�cancer. It has operations in Indianapolis and West Lafayette, the US. Endocyte is headquartered in West Lafayette, Indiana, the US.

Endocyte Inc (ECYT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents

List of Tables

List of Figures

Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Endocyte Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018

Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018

Endocyte Inc, Medical Devices Deals, 2012 to YTD 2018

Endocyte Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018

Endocyte Inc, Pharmaceuticals & Healthcare, Deal Details

Partnerships

Endocyte Enters into Agreement Seattle Children's Research Institute

Licensing Agreements

Endocyte Receives Rights from Radiomedix

Endocyte Enters into Licensing Agreement with ABX

Endocyte Enters into Licensing Agreement with Nihon Medi-Physics for Etarfolatide

Equity Offering

Endocyte Raises USD86.3 Million in Public Offering of Shares

Endocyte Plans to Raise up to USD150 Million in Public Offering of Securities

Endocyte Raises Funds through Private Placement of Shares and Warrants

Endocyte Raises USD4.5 Million in Private Placement of Shares upon Exercise of Warrants

Endocyte Completes Public Offering Of Shares For USD108.7 Million

Endocyte Inc-Key Competitors

Endocyte Inc-Key Employees

Endocyte Inc-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Recent Developments

Financial Announcements

Feb 26, 2018: Endocyte Announces Phase 3 VISION Trial and Provides Update on Corporate Strategy and Reports Fourth Quarter and Year End 2017 Financial Results

Nov 06, 2017: Endocyte Reports Third Quarter Financial Results

Aug 08, 2017: Endocyte Reports Second Quarter Financial Results and Provides Clinical and Pipeline Update

May 10, 2017: Endocyte Reports First Quarter Financial Results and Provides Clinical and Pipeline Update

Mar 10, 2017: Endocyte Reports Fourth Quarter and Year End 2016 Financial Results and Provides Clinical and Pipeline Update

Corporate Communications

Feb 27, 2018: Endocyte Appoints Patrick Machado, J.D. to Its Board of Directors

Feb 21, 2017: Endocyte Appoints Michael T. Andriole as Chief Financial Officer

Product News

10/17/2017: New Potential Treatment for Prostate Cancer Receives Boost

Clinical Trials

Sep 05, 2017: Endocyte Announces Presentation at the European Society for Medical Oncology

Jun 02, 2017: Endocyte Announces Clinical Update for EC1169

May 26, 2017: Endocyte to Announce Updated Data on clinical-stage asset EC1169 at the 2017 American Society of Clinical Oncology Annual Meeting

Appendix

Methodology

About GlobalData

Contact Us

Disclaimer

List of Figures

Endocyte Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018

Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Endocyte Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018

Endocyte Inc, Medical Devices Deals, 2012 to YTD 2018

List of Tables

Endocyte Inc, Pharmaceuticals & Healthcare, Key Facts, 2016

Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Endocyte Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018

Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Endocyte Inc, Deals By Therapy Area, 2012 to YTD 2018

Endocyte Inc, Medical Devices Deals, 2012 to YTD 2018

Endocyte Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018

Endocyte Enters into Agreement Seattle Children's Research Institute

Endocyte Receives Rights from Radiomedix

Endocyte Enters into Licensing Agreement with ABX

Endocyte Enters into Licensing Agreement with Nihon Medi-Physics for Etarfolatide

Endocyte Raises USD86.3 Million in Public Offering of Shares

Endocyte Plans to Raise up to USD150 Million in Public Offering of Securities

Endocyte Raises Funds through Private Placement of Shares and Warrants

Endocyte Raises USD4.5 Million in Private Placement of Shares upon Exercise of Warrants

Endocyte Completes Public Offering Of Shares For USD108.7 Million

Endocyte Inc, Key Competitors

Endocyte Inc, Key Employees

Endocyte Inc, Other Locations

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

select a license

Single User License
USD 250 INR 16863
Site License
USD 500 INR 33725
Corporate User License
USD 750 INR 50588

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com